Recent insider trends for Halozyme Therapeutics, Inc. (NASDAQ:HALO) have caught the attention of investors. Insider data is useful because it can reveal what a company’s executives and largest shareholders feel about a stock. In this case, the data has some interesting things to say about how HALO might perform in the future.
Institutions own 85.85% of Halozyme Therapeutics, Inc. (HALO)’s shares. The total value of these holdings, in millions, is $1,606. Among active positions in the latest quarter, 102 holders increased their positions by a total of 11.49 million shares, 57 holders decreased the positions by a total of 4.33 million shares, and 26 holders held their positions. This works out to a net increase in ownership of 7.16 million shares, and suggests that institutions are feeling bullish about the stock.
Among new and sold out positions, 25 holders initiated new positions by a total of 3.14 million shares and 18 holders exited their positions by a total of 592151 shares. This nets out to an increase of 2.55 million shares and is a bullish sign for HALO.
In the last three months, insiders executed a total of 2 trades. 1 of these were buys and 1 were sells. Insider ownership decreased by a total of 1.74 million shares, which suggests that HALO’s key executives are feeling less optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: insiders executed 8 buys and 6 sells, and ownership decreased by a net of 1.67 million shares.
Short interest is another tool that analysts use to gauge investor sentiment. It represents the number of a stock’s shares that are being shorted by investors. Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s short interest is 20.36 million shares, or 18.85% of the float. This represents a decrease of -2% in the number of shares being shorted compared to the previous reading, and implies that investors felt less pessimistic about the stock during the past two weeks.
Supplementing insider data with technical indicators can help an investor form a more complete view on the outlook for a stock. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that HALO is a buy, which implies that HALO is expected to outperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bearish. Technical indicators (also) suggest that Halozyme Therapeutics, Inc. (NASDAQ:HALO) is undervalued.